Scancell Holdings plc (AIM:SCLP)
23.45
+1.45 (6.59%)
May 26, 2026, 4:22 PM GMT
Scancell Holdings Revenue
Scancell Holdings had revenue of 4.71M GBP in the twelve months ending October 31, 2025. In the fiscal year ending April 30, 2025, Scancell Holdings had annual revenue of 4.71M.
Revenue
4.71M
Revenue Growth
n/a
P/S Ratio
50.67
Revenue / Employee
78.52K
Employees
60
Market Cap
238.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 4.71M | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | 5.27M | - | - |
| Apr 30, 2022 | - | - | - |
| Apr 30, 2021 | - | - | - |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Oxford Nanopore Technologies | 223.90M |
| Oxford Biomedica | 168.74M |
| hVIVO | 49.66M |
| Bioventix | 12.54M |
| PureTech Health | 3.46M |
| 4basebio | 1.69M |
| Ondine Biomedical | 1.18M |
| Faron Pharmaceuticals Oy | 1.14M |
Scancell Holdings News
- 4 weeks ago - FDA Grants Fast Track Designation To Scancell For ISCIB1+ In Treating Advanced Melanoma - Nasdaq
- 4 weeks ago - Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study - GlobeNewsWire
- 4 months ago - Scancell Holdings Earnings Call Transcript: H1 2026 - Transcripts
- 4 months ago - Scancell Holdings Quarterly report: H1 2026 - Filings
- 4 months ago - Scancell Holdings Slides: H1 2026 - Filings
- 4 months ago - Scancell Holdings Earnings Call Transcript: H1 2026 - Transcripts
- 4 months ago - Scancell Holdings Quarterly report: H1 2026 - Filings
- 4 months ago - Scancell Holdings Slides: H1 2026 - Filings